-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Upgrades Regulus Therapeutics to Overweight, Raises Price Target to $6

Benzinga·03/27/2025 18:06:17
Listen to the news
Wells Fargo analyst Yanan Zhu upgrades Regulus Therapeutics (NASDAQ:RGLS) from Equal-Weight to Overweight and raises the price target from $3 to $6.